-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
Axsome Therapeutics today announced positive results from the Phase II Ascend clinical trial of major depressive disorder (MDD) therapy AXS-05, published in the American Journal of Psychiat.
Results of the Phase II trial published here demonstrate rapid, substantial and statistically significant reductions in depressive symptoms and induction of remission in patients treated with AXS-05 compared to patients with moderate to severe MDD treated with bupropion alone improvement in meani.
Therapy with AXS-05 entails taking a 45 mg tablet once daily for three days, followed by two daily doses for a total of six wee.
Major depressive disorder is also known as clinical depressi.
Typically, major depressive disorder is often treated with antidepressants, most commonly serotonin reuptake inhibitors (SSRI.
Dan Iosifescu,.
The AXS-05 therapy, with more than 40.
In another Phase III GEMINI trial involving 327 adults with moderate-to-severe depression, AXS-05 therapy rapidly and significantly improved depressive symptoms compared with placebo, meeting the trial's primary endpoi.
In addition, Axsome is also investigating the therapeutic's efficacy in Alzheimer's disea.
Reference source:
Axsome Takes New Approach, Targets NMDA Receptors to Treat Depression
